Journal - Current Pharmaceutical Analysis

Current Pharmaceutical Analysis

Starting from Volume 21, CPA will be published by KeAi Publishing (The journal homepage is under construction)

All Open Access articles of this journal are also available on ScienceDirect.

Impact Factor: 0.7

Indexed in: Scopus, SCI Expanded, JCR... View all

Volume 20 , Issues 9, 2024

Institutional Members

Impact Factor

Current: 0.7
5 - Year: 0.7

Ranking & Category

239th of 261 in Pharmacology & Pharmacy

Topic(s) Covered

1 Topic(s)

View

Aims & Scope

Current Pharmaceutical Analysis publishes full-length/mini reviews and original research articles on all the most recent advances in pharmaceutical and biomedical analysis. All aspects of the field are represented including drug analysis, analytical methodology and instrumentation. The journal is essential to all involved in pharmaceutical, biochemical and clinical analysis.

Abstracted & Indexed in:

British Library Cabell's Directory/Journalytics Cambridge Scientific Abstracts (CSA)/ProQuest Chemical Abstracts Service/SciFinder CNKI Scholar EBSCO EMBASE ERA 2018 Essential Science Indicators Genamics Journal Seek Google Scholar Index Copernicus J-Gate Journal Citation Reports/Science Edition JournalTOCs MediaFinder®-Standard Periodical Directory OpenAire PubsHub QOAM Science Citation Index Expanded™ (SciSearch®) Scilit Scopus Suweco CZ Ulrich's Periodicals Directory

Archiving and Copyright:

Portico Sherpa Romeo

Journal Database:

Dimensions

Archived in

Announcement for Authors

As a special promotion to our authors, there will be a 50% waiver on Page charges on the submission of research articles, between 1^st July and 30^th September 2022. This will be a saving of US$325 on the article processing charges (APC) if authors wish to publish research articles in this journal.

Click here to submit your paper now!

Endorsement(s)

"It is a great privilege for Pharmaceutical and Biomedical scientists to access convincing and state-of-the-art reviews through Current Pharmaceutical Analysis."

Ilias Jimidar
Johnson & Johnson Pharmaceutical R&D, Belgium